In this episode Prof. Gavin Giovannoni explains what smouldering MS is, and why he calls it "the real MS".

Detecting smouldering MS in clinical practice can be challenging. In this episode Prof. Guy Laureys talks about how to monitor subtle disease progression.

Brain atrophy is one of the most destructive consequences of MS. In this episode we meet Professor Robert Zivadinov, who will take a closer look at brain atrophy and other brain measures in explaining physical disability in MS.

In this episode of The MS podcast we speak to Finnish professor Laura Airas about the role of microglia in the progression of MS. Tune in to hear about microglia as a marker for disease progression, how PET imaging can be used to detect innate immune cell activation and more.

EBV is one of the most common human viruses. In this episode we look closer at the role of EBV in MS and its association with Brain MRI images with Professor Robert Zivadinov from the Buffalo Neuroimaging Analysis Center.

GZNO.MS.19.11.0310

What happens when our cognitive functioning is challenged – which is the case for many people living with MS? To shed some light on the impact of cognitive decline and the future perspectives for cognitive rehabilitation in MS, we have the pleasure of having Hanneke Hulst, assistant professor from the MS center in Amsterdam, (Amsterdam UMC – VUmc), in the studio for this episode.

October, 2020.

GZNO.MS.19.11.0310

MAT-GLB-2003397-v1.0

Biomarkers are important in MS, as they can potentially help with diagnosing patients, inform about disease prognosis, and help monitor disease activity and progression. Neurofilament light chain (NfL) is one of the most promising biomarkers in MS, but is it ready for clinical practice? In this episode, Professor of Neurology Finn Sellebjerg will tell us about the potential and limitations of this exciting biomarker.

GZNO.MS.19.11.0310

MAT-GLB-2003322-v1.0

In this episode we’ll talk more about what hides behind the structures of our brain, in the core of the thalamus. Thalamic atrophy measurements have existed for a long time, but within MS it is quite new to look into the thalamic atrophy, also as a biomarker. Today’s guest, Prof. Dr. Cristina Granziera, will tell us more about how knowledge about thalamic atrophy can be implemented in clinical practice.

GZNO.MS.19.11.0310

MAT-GLB-2003396-v1.0

MS has long been considered a disease of focal white matter lesions, but recent studies have highlighted the importance of diffuse occult brain damage. Are we facing a paradigm shift? In this episode we'll talk to Dr. Jens Wuerfel about deep grey matter atrophy and advanced imaging to reveal and quantify occult damage of the CNS.

GZNO.MS.19.11.0310

MAT-GLB-2003394-v1.0

Guest host Svend Geertsen, Medical Advisor for MS in Sanofi Genzyme Denmark, will in this episode discuss the relevance and challenges with measuring brain atrophy with brain imaging experts Morten Blinkenberg, Senior Consultant at the Danish Multiple Sclerosis Center at Rigshospitalet, and Professor Hartwig Siebner, Head of Research at the Danish Research Centre for Magnetic Resonance at Hvidovre Hospital.

GZNO.MS.19.11.0310

MAT-GLB-2003317-v1.0